Hemosol

HML-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about HML-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
August 9, 2005
This could be a time when money moves back into the health care. Usually the small cap biotech stocks, such as Biovale (BVF-T), Patheon (PTI-T), MDS (MDS-T), etc. move together. Don't just buy one, buy 3 or 4 of them. This one is a pretty thin trader, so would stay away from it.
Hemosol (HML-T)
August 9, 2005
This could be a time when money moves back into the health care. Usually the small cap biotech stocks, such as Biovale (BVF-T), Patheon (PTI-T), MDS (MDS-T), etc. move together. Don't just buy one, buy 3 or 4 of them. This one is a pretty thin trader, so would stay away from it.
Bill Carrigan
Technical Analyst, Getting Technical Info Service
Price
$1.500
Owned
Unknown
DON'T BUY
DON'T BUY
June 13, 2005
Consolidated stock at 4 to 1 to meet Nasdaq requirements. Markets hate reverse consolidations. Typically it's not a good sign as it means you've got too many shares outstanding. Not a great company, so wouldn't expect a whole lot from this company in the future.
Hemosol (HML-T)
June 13, 2005
Consolidated stock at 4 to 1 to meet Nasdaq requirements. Markets hate reverse consolidations. Typically it's not a good sign as it means you've got too many shares outstanding. Not a great company, so wouldn't expect a whole lot from this company in the future.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$1.750
Owned
No
VAGUE
VAGUE
February 9, 2004
Speculative future.
Hemosol (HML-T)
February 9, 2004
Speculative future.
Michael Sprung
President, Sprung Investment Management
Price
$1.580
Owned
Unknown
BUY
BUY
January 28, 2004
It will expire again, company has run out of money many times. Take money out, while money is on the table.
Hemosol (HML-T)
January 28, 2004
It will expire again, company has run out of money many times. Take money out, while money is on the table.
Andrew McCreath
Senior Portfolio Manager, Sentry Select Capital
Price
$1.620
Owned
Unknown
SELL
SELL
January 26, 2004
Basically, you are paying for an option. The company has run out of money many times and they continue to have regulatory problems with their product.
Hemosol (HML-T)
January 26, 2004
Basically, you are paying for an option. The company has run out of money many times and they continue to have regulatory problems with their product.
Andrew McCreath
Senior Portfolio Manager, Sentry Select Capital
Price
$1.560
Owned
No
DON'T BUY
DON'T BUY
December 15, 2003
Built a nice plant in Mississauga, but found they had trouble with their blood substitute. Now a speculative stock.
Hemosol (HML-T)
December 15, 2003
Built a nice plant in Mississauga, but found they had trouble with their blood substitute. Now a speculative stock.
Gavin Graham
Trustee, Pointbreak ETFs
Price
$1.580
Owned
No
DON'T BUY
DON'T BUY
December 8, 2003
Have made arrangements with another biotech company by contracting for part of their facility. Should be getting some revenues. Not a fan.
Hemosol (HML-T)
December 8, 2003
Have made arrangements with another biotech company by contracting for part of their facility. Should be getting some revenues. Not a fan.
Robert Floyd
President, R A Floyd Management
Price
$1.700
Owned
No
DON'T BUY
DON'T BUY
December 8, 2003
A speculative play. Hemalink stalled in face two clinical trials. Build a plant. Limited visibility going forward.
Hemosol (HML-T)
December 8, 2003
A speculative play. Hemalink stalled in face two clinical trials. Build a plant. Limited visibility going forward.
John Sinkins, CFA
Senior Portfolio Manager, Sentry Select Capital Corp
Price
$1.700
Owned
Unknown
DON'T BUY
DON'T BUY
September 5, 2003
Ran into trouble with their lead product. Down to about $900,000 in cash. The company is on life support.
Hemosol (HML-T)
September 5, 2003
Ran into trouble with their lead product. Down to about $900,000 in cash. The company is on life support.
Lou Schizas
Business Editor, Market Call
Price
$0.870
Owned
Unknown
DON'T BUY
DON'T BUY
March 31, 2003
Very speculative. FDA trials didn't go well.
Hemosol (HML-T)
March 31, 2003
Very speculative. FDA trials didn't go well.
John Sinkins, CFA
Senior Portfolio Manager, Sentry Select Capital Corp
Price
$0.720
Owned
Unknown
DON'T BUY
DON'T BUY
March 17, 2003
A lot of problems. May not survive.
Hemosol (HML-T)
March 17, 2003
A lot of problems. May not survive.
Glenn Paradis, BA, CFA
Vice President & Sr Portfolio Manager, Equities, Aegon Capital Management Inc.
Price
$0.620
Owned
Unknown
DON'T BUY
DON'T BUY
January 14, 2003
A long way from being a mature company with mature products. Speculative.
Hemosol (HML-T)
January 14, 2003
A long way from being a mature company with mature products. Speculative.
David Baskin
President, Baskin Wealth Management
Price
$2.890
Owned
Unknown
DON'T BUY
DON'T BUY
January 14, 2003
Never seems to get it together.
Hemosol (HML-T)
January 14, 2003
Never seems to get it together.
Michael Smedley
Exec VP & Chief Investment Officer, Morgan Meighan & Associates
Price
$2.890
Owned
Unknown
DON'T BUY
DON'T BUY
December 5, 2002
Worst is behind them. Would prefer owning through MDS.
Hemosol (HML-T)
December 5, 2002
Worst is behind them. Would prefer owning through MDS.
John Zechner
Chairman, J. Zechner & Assoc
Price
$2.500
Owned
Unknown
WEAK BUY
WEAK BUY
November 7, 2002
OK for a long term hold. Buy on weakness.
Hemosol (HML-T)
November 7, 2002
OK for a long term hold. Buy on weakness.
Bruce Campbell (1)
President, Campbell and Lee InvMngmnt
Price
$1.900
Owned
Unknown
DON'T BUY
DON'T BUY
November 1, 2002
Has some problems. Cash position is down to one year. If they issue stocks to rais cash, it will dilute these shares further.
Hemosol (HML-T)
November 1, 2002
Has some problems. Cash position is down to one year. If they issue stocks to rais cash, it will dilute these shares further.
Robert Floyd
President, R A Floyd Management
Price
$1.290
Owned
Unknown
DON'T BUY
DON'T BUY
October 2, 2002
Very risky situation. May have to dilute stock by issuing more shares.
Hemosol (HML-T)
October 2, 2002
Very risky situation. May have to dilute stock by issuing more shares.
Mike Weir
Managing Director, Guardian Capital
Price
$1.130
Owned
Unknown
DON'T BUY
DON'T BUY
September 20, 2002
Could run out of cash.
Hemosol (HML-T)
September 20, 2002
Could run out of cash.
Gavin Graham
Trustee, Pointbreak ETFs
Price
$0.850
Owned
Unknown
DON'T BUY
DON'T BUY
August 20, 2002
Had delays in getting product out. A lot of cash. Risky unless you buy several small pharmaceuticals to spread the risk.
Hemosol (HML-T)
August 20, 2002
Had delays in getting product out. A lot of cash. Risky unless you buy several small pharmaceuticals to spread the risk.
Gavin Graham
Trustee, Pointbreak ETFs
Price
$1.070
Owned
Unknown
DON'T BUY
DON'T BUY
August 19, 2002
Has cash burn and has to raise money. Speculative.
Hemosol (HML-T)
August 19, 2002
Has cash burn and has to raise money. Speculative.
David Baskin
President, Baskin Wealth Management
Price
$1.030
Owned
Unknown
DON'T BUY
DON'T BUY
May 2, 2002
Have had a tough time getting approval. Competition is growing. Future is uncertain.
Hemosol (HML-T)
May 2, 2002
Have had a tough time getting approval. Competition is growing. Future is uncertain.
Bruce Cooper
Portfolio Manager, T.D. Asset
Price
$3.750
Owned
Unknown
DON'T BUY
DON'T BUY
April 29, 2002
Hard to like.
Hemosol (HML-T)
April 29, 2002
Hard to like.
Michael Smedley
Exec VP & Chief Investment Officer, Morgan Meighan & Associates
Price
$3.900
Owned
Unknown
DON'T BUY
DON'T BUY
April 25, 2002
Disappointed with their product results. High burn rate.
Hemosol (HML-T)
April 25, 2002
Disappointed with their product results. High burn rate.
Robert Floyd
President, R A Floyd Management
Price
$4.000
Owned
Unknown
DON'T BUY
DON'T BUY
April 18, 2002
Has disappointed. Not convinced about the needs for blood substitute.
Hemosol (HML-T)
April 18, 2002
Has disappointed. Not convinced about the needs for blood substitute.
Glenn Paradis, BA, CFA
Vice President & Sr Portfolio Manager, Equities, Aegon Capital Management Inc.
Price
$4.600
Owned
Unknown
DON'T BUY
DON'T BUY
April 3, 2002
Treat as a trading stock. No value right now.
Hemosol (HML-T)
April 3, 2002
Treat as a trading stock. No value right now.
David Driscoll
President & CEO, Liberty International Investment Management Inc
Price
$4.580
Owned
Unknown
DON'T BUY
DON'T BUY
April 2, 2002
Only has one drug. Needds more diversification.
Hemosol (HML-T)
April 2, 2002
Only has one drug. Needds more diversification.
Joe Connolly
Director of Resource and Trading, Cockfield Porretti Cunningham
Price
$4.620
Owned
Unknown
DON'T BUY
DON'T BUY
March 21, 2002
Approval of Hemolink was denied. No revenues or earnings.
Hemosol (HML-T)
March 21, 2002
Approval of Hemolink was denied. No revenues or earnings.
Bruce Cooper
Portfolio Manager, T.D. Asset
Price
$4.200
Owned
Unknown
DON'T BUY
DON'T BUY
March 21, 2002
Too much competition.
Hemosol (HML-T)
March 21, 2002
Too much competition.
Joe Connolly
Director of Resource and Trading, Cockfield Porretti Cunningham
Price
$4.200
Owned
Unknown
BUY
BUY
March 20, 2002
At a good price and a good buy for an aggressive investor.
Hemosol (HML-T)
March 20, 2002
At a good price and a good buy for an aggressive investor.
Rob Callander
Vice President and Portfolio Manager, Caldwell Securities
Price
$5.880
Owned
Unknown
DON'T BUY
DON'T BUY
February 19, 2002
A one trick pony. Speculative.
Hemosol (HML-T)
February 19, 2002
A one trick pony. Speculative.
David Baskin
President, Baskin Wealth Management
Price
$6.290
Owned
Unknown
Showing 1 to 30 of 78 entries